These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 38349726)

  • 21. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.
    Schneider CV; Schneider KM; Raptis A; Huang H; Trautwein C; Loomba R
    Aliment Pharmacol Ther; 2024 May; 59(10):1271-1281. PubMed ID: 38500443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AKR1B1 drives hyperglycemia-induced metabolic reprogramming in MASLD-associated hepatocellular carcinoma.
    Syamprasad NP; Jain S; Rajdev B; Panda SR; Kumar GJ; Shaik KM; Shantanu PA; Challa VS; Jorvekar SB; Borkar RM; Vaidya JR; Tripathi DM; Naidu VGM
    JHEP Rep; 2024 Feb; 6(2):100974. PubMed ID: 38283757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Manifestation and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Predominately African American Population at a Multi-Specialty Healthcare Organization.
    Saini A; Rutledge B; Damughatla AR; Rasheed M; Naylor P; Mutchnick M
    Healthcare (Basel); 2024 Jul; 12(15):. PubMed ID: 39120181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.
    Younossi ZM; Golabi P; Price JK; Owrangi S; Gundu-Rao N; Satchi R; Paik JM
    Clin Gastroenterol Hepatol; 2024 Oct; 22(10):1999-2010.e8. PubMed ID: 38521116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Precision medicine and nucleotide-based therapeutics to treat MASH.
    Caddeo A; Romeo S
    Clin Mol Hepatol; 2024 Aug; ():. PubMed ID: 39103998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients.
    Paklar N; Mijic M; Filipec-Kanizaj T
    Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RASSF4 Attenuates Metabolic Dysfunction-Associated Steatotic Liver Disease Progression via Hippo Signaling and Suppresses Hepatocarcinogenesis.
    Xu C; Fang T; Qu J; Miao Y; Tian L; Zhang M; Zhuang H; Sun B; Chen L
    Cell Mol Gastroenterol Hepatol; 2024; 18(2):101348. PubMed ID: 38697356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.
    Armandi A; Bugianesi E
    Eur J Intern Med; 2024 Apr; 122():20-27. PubMed ID: 38262842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review.
    Ghazanfar H; Javed N; Qasim A; Zacharia GS; Ghazanfar A; Jyala A; Shehi E; Patel H
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
    Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
    Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pathophysiology of MASLD: an immunometabolic perspective.
    Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H
    Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options.
    Shi Y; Taherifard E; Saeed A; Saeed A
    Curr Issues Mol Biol; 2024 Jun; 46(6):5965-5983. PubMed ID: 38921027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis.
    Ramos-Molina B; Rossell J; Pérez-Montes de Oca A; Pardina E; Genua I; Rojo-López MI; Julián MT; Alonso N; Julve J; Mauricio D
    Front Endocrinol (Lausanne); 2024; 15():1400961. PubMed ID: 38962680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.
    Ortiz-López N; Madrid AM; Aleman L; Zazueta A; Smok G; Valenzuela-Pérez L; Poniachik J; Beltrán CJ
    Front Med (Lausanne); 2024; 11():1376148. PubMed ID: 38854668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease.
    Núñez-Sánchez MÁ; Martínez-Sánchez MA; Sierra-Cruz M; Lambertos A; Rico-Chazarra S; Oliva-Bolarín A; Balaguer-Román A; Yuste JE; Martínez CM; Mika A; Frutos MD; Llamoza-Torres CJ; Córdoba-Chacón J; Ramos-Molina B
    J Pathol; 2024 Sep; 264(1):101-111. PubMed ID: 39022853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease.
    Younossi ZM; Stepanova M; Al Shabeeb R; Eberly KE; Shah D; Nguyen V; Ong J; Henry L; Alqahtani SA
    Hepatol Commun; 2024 Jan; 8(1):. PubMed ID: 38126928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver Tissue Proteins Improve the Accuracy of Plasma Proteins as Biomarkers in Diagnosing Metabolic Dysfunction-Associated Steatohepatitis.
    Sourianarayanane A; Salemi MR; Phinney BS; McCullough AJ
    Proteomics Clin Appl; 2024 Jul; ():e202300236. PubMed ID: 39073724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global research trends on gut microbiota and metabolic dysfunction-associated steatohepatitis: Insights from bibliometric and scientometric analysis.
    Alam N; Jia L; Cheng A; Ren H; Fu Y; Ding X; Haq IU; Liu E
    Front Pharmacol; 2024; 15():1390483. PubMed ID: 39070791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
    Abushamat LA; Shah PA; Eckel RH; Harrison SA; Barb D
    Clin Gastroenterol Hepatol; 2024 Aug; 22(8):1565-1574. PubMed ID: 38367743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.